Aged garlic extract liquid 2.4 mL/day,
does it really help with Prevention of colorectal-adenoma recurrence?
research showsGrade C with 46 points. Among 37 efficacy-evaluable participants from 51 randomized, new adenomas were reported in 9/19 high-dose and 12/18 low-dose participants (RR 0.71). Only lesions larger than 5 mm were removed, so smaller lesions could remain; the contrast also lacks a reported confidence interval, P value, prospective registration, and ITT analysis and cannot confirm prevention after complete removal.
ads claimThis cannot be extended to colorectal-cancer prevention or complete polyp prevention.
Useful facts when choosing a product
- This verdict applies only to the displayed formulation, route, dose, duration, population, endpoint, and comparator.
- Raw garlic, powder, garlic oil, stabilized-allicin products, aged garlic extract, black garlic, fermented garlic, and isolated S-allylcysteine are not interchangeable.
- Caution. A small one-year study cannot establish long-term chemoprevention safety; review antithrombotic and peri-procedural use.
Chamgap Semantic Classification Code
Permanent code issued
S.aged-garlic-extract.oral.colorectal-adenoma-recurrence.reduce.low-doseSupplements and nutraceuticals > Aged garlic extract > Oral > Colorectal-adenoma recurrence > Reduction claim > Low-dose AGE
Bound to high- versus low-dose AGE and presence of adenoma on follow-up colonoscopy. Only lesions over 5 mm were removed, so this differs from recurrence after complete removal; count, size, and cancer are separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | High-dose aged garlic extract |
| Source or part used | Aged Allium sativum L. clove extract |
| Formulation or processing | Capsules equivalent to liquid AGE; SAC and dry-matter equivalents unverified |
| Route | Oral |
| Dose | High dose 2.4 mL/day versus low dose 0.16 mL/day |
| Duration | 12 months with colonoscopy at 6 and 12 months |
| Population | 51 adults with prior adenomas after removal of lesions larger than 5 mm; smaller lesions could remain |
| Effect or condition | Reduced recurrence of at least one adenoma |
| Primary endpoint | Proportion with at least one new adenoma over 0-12 months |
| Comparator | Low-dose AGE 0.16 mL/day |
| Duplicate-detection key | High-dose aged garlic extract|Capsules equivalent to liquid AGE; SAC and dry-matter equivalents unverified|Oral|51 adults with prior adenomas after removal of lesions larger than 5 mm; smaller lesions could remain|Reduced recurrence of at least one adenoma|12 months with colonoscopy at 6 and 12 months |
What the research actually shows
The 51 randomized and 37 efficacy-evaluable denominators were separated, and later-interval P values were not attached to the representative endpoint.
Why this is classified as C (46)
Adenoma is a precancerous surrogate (S); product involvement (I1), EX, an active comparator, 27% efficacy-analysis exclusion, and a small sample (B2) yield C/46.
Counterpoint. RR 0.71 is promising, but event counts are small, the exact CI is missing, and independent confirmation is absent.
Rejudgment record. Independent Codex cross-check — One formulation, route, population, claim, principal endpoint, and comparator
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Effects of aged garlic extract (AGE) on colorectal adenomas: a double-blinded study | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 37 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-08).
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] High-Dose Aged Garlic Extract for Colorectal-Adenoma Recurrence—A 9/19 Versus 12/18 Signal, Not Confirmation — Evidence Grade C·46. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/high-dose-aged-garlic-extract-colorectal-adenoma-recurrence/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.